<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910075</url>
  </required_header>
  <id_info>
    <org_study_id>1U01NS106655-01A1</org_study_id>
    <nct_id>NCT03910075</nct_id>
  </id_info>
  <brief_title>Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)</brief_title>
  <acronym>I-ACQUIRE</acronym>
  <official_title>Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Polytechnic Institute and State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Polytechnic Institute and State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III clinical trial to compare the efficacy of two dosages of a new infant
      rehabilitation protocol - I-ACQUIRE - to usual and customary forms of infant rehabilitation
      in infants who experienced Perinatal Arterial Stroke (PAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a Phase III trial powered to determine efficacy of two different doses
      of I-ACQUIRE for children 8 to 36 months old with PAS and hemiparesis. The design is a
      prospective Randomized Controlled Trial (RCT) in which 240 children will be randomly assigned
      to one of 3 treatment groups (N=80 per group): 1) Moderate Dose I-ACQUIRE (3 hrs/day, 5
      day/wk X 4 wks), 2) High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks), or 3) Usual and
      Customary Treatment (U&amp;CT). I-ACQUIRE will be delivered by protocol-trained therapists and
      monitored weekly for dosage and treatment fidelity; U&amp;CT will be provided by community
      therapists with dosage and approaches documented weekly. All primary and secondary efficacy
      outcomes rely on blinded assessments at baseline, end of treatment, and 6 mos post-treatment.
      Exploratory outcomes and supplemental clinical measures may provide valuable additional data
      about development and health in this sample of children with PAS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Emerging Behaviors Scale (EBS) Score</measure>
    <time_frame>Both immediately after treatment (within 7 days) and 6 months (plus or minus 2 months) post-treatment</time_frame>
    <description>The primary efficacy is measured by the Emerging Behaviors Scale (EBS) that counts the number of upper extremity skills on the hemiparetic side that the child displays (from 0 to 30). The source for observation comes from a battery of standardized age-appropriate neuromotor assessment tools (Gross Motor Function Measure-66, The Bayley III Fine and Gross Motor scales, unilateral skills during the Mini AHA) and independent observational coding of the videotaped assessment session with supplemental parent ratings on the Infant Motor Activity Log and daily skills on the MacArthur-Bates Communicative Development Inventory. A favorable outcome is defined as a gain of ≥7 new EBS skills above the child's baseline (pre-treatment) score. The EBS requires evidence of each skill from at least two independent sources.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Bilateral Use of the Hemiparetic Upper Extermity based on the Mini-Assisting Hand Assessment (Mini-AHA) play assessment</measure>
    <time_frame>Both immediately after treatment (within 7 days) and 6 months (plus or minus 2 months) post-treatment</time_frame>
    <description>The secondary efficacy outcome is measured by increases in the use of the hemiparetic upper extremity while engaged in bilateral activities during the interactive play session of the Mini-AHA. Each item is scored on a 4-pt scale where the points are behaviorally anchored and adjusted for the child's age range. Raw scores are converted into a summary Logit score (0 to 100) based on Item Response Theory analyses, indicating the relative difficulty and sequence in which certain levels of performance appear. For this metric, higher scores are considered better.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Perinatal Stroke</condition>
  <condition>Hemiparesis</condition>
  <arm_group>
    <arm_group_label>I-ACQUIRE High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I-ACQUIRE Moderate Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual &amp; Customary Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual &amp; Customary Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>I-ACQUIRE - High Dosage</intervention_name>
    <description>Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.</description>
    <arm_group_label>I-ACQUIRE High Dose</arm_group_label>
    <other_name>ACQUIRE</other_name>
    <other_name>Pediatric Constraint-Induced Movement Therapy</other_name>
    <other_name>P-CIMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>I-ACQUIRE - Moderate Dosage</intervention_name>
    <description>Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.</description>
    <arm_group_label>I-ACQUIRE Moderate Dose</arm_group_label>
    <other_name>ACQUIRE</other_name>
    <other_name>Pediatric Constraint-Induced Movement Therapy</other_name>
    <other_name>P-CIMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual &amp; Customary Treatment (U&amp;CT)</intervention_name>
    <description>Children in this group will receive the same U&amp;CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.</description>
    <arm_group_label>Usual &amp; Customary Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  child will be 8 - 36 months old when study treatment will be delivered

          -  child has a diagnosis of Perinatal Arterial Stroke (PAS)

          -  parent permission to provide the child's clinical MRI to the study

          -  child has hemiparesis

          -  parent(s) willing to participate in the home therapy component

          -  one parent English language proficient and will take the lead in interacting with
             study staff and completing self-administered forms and interviews in English

        Exclusion Criteria:

          -  child has medical or sensory condition(s) that prevent(s) full therapy participation
             (e.g., frequent uncontrolled seizures, fragile health)

          -  child previously received Constraint-Induced Movement Therapy (CIMT) or modified CIMT
             with a dose of at least 2 hrs/day for ≥10 days

          -  child received botulinum toxin in past 3 months

          -  child is a ward of the state or other agency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon L Ramey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Polytechnic Institute and State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren Lo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Bateman, B.S.</last_name>
    <phone>540-526-2033</phone>
    <email>laurapb2@vt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie DeLuca, Ph.D.</last_name>
    <phone>540-526-2098</phone>
    <email>Stephdeluca@vt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USCD Health La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Trauner, MD</last_name>
      <phone>858-966-5819</phone>
      <email>dtrauner@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Reit, MPH</last_name>
      <phone>619-253-0477</phone>
      <email>jreit@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Doris Trauner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Gold, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dylan Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ment, MD</last_name>
      <phone>203-785-5708</phone>
      <email>laura.ment@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Hoffman, BS</last_name>
      <phone>203-737-6894</phone>
      <email>Taylor.hoffman@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Ment, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Albuja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Betty Vohr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Burton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Ionita, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gyula Acsadi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lehman, MD</last_name>
      <phone>617-355-2758</phone>
      <email>laura.lehman@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Swanson</last_name>
      <phone>617-919-1446</phone>
      <email>julie.swanson@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Lehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Musolino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Rivkin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Pruente, MD</last_name>
      <phone>734-936-7175</phone>
      <email>jpruente@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bre'Anna Simpson</last_name>
      <phone>734-615-4630</phone>
      <email>sbreanna@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Pruente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Hurvitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Taylor, MD</last_name>
      <phone>513-636-4222</phone>
      <email>JM.Taylor@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Victor LaFay, MBA</last_name>
      <phone>513-803-1988</phone>
      <email>Victor.LaFay@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Harpster, PhD/OTR/L</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martha Morehouse Medical Plaza</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Darragh, PhD</last_name>
      <phone>614-293-3760</phone>
      <email>amy.darragh@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Tanner, phD</last_name>
      <phone>614-722-8697</phone>
      <email>kelly.tanner@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Darragh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jill Heathcock, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Prosser, PT, PhD</last_name>
      <phone>215-301-4301</phone>
      <email>prosserl@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Noor Ruwaih</last_name>
      <phone>267-426-7032</phone>
      <email>ruwaihn@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Prosser, PT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Ichord, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fralin Biomedical Research Institute at Virginia Tech</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie DeLuca, PhD</last_name>
      <phone>540-526-2098</phone>
      <email>stephdeluca@vt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Lou Schwarzer, OTA</last_name>
      <phone>540-526-2202</phone>
      <email>mary73@vt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie DeLuca, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Virginia Polytechnic Institute and State University</investigator_affiliation>
    <investigator_full_name>Sharon Ramey</investigator_full_name>
    <investigator_title>Distinguished Research Scholar and Professor</investigator_title>
  </responsible_party>
  <keyword>P-CIMT</keyword>
  <keyword>Pediatric Constraint-Induced Movement Therapy</keyword>
  <keyword>Hemiparesis</keyword>
  <keyword>Perinatal Stroke</keyword>
  <keyword>Neonatal Stroke</keyword>
  <keyword>Pediatric rehabilitation</keyword>
  <keyword>Infant therapy</keyword>
  <keyword>Cerebral Palsy</keyword>
  <keyword>ACQUIRE</keyword>
  <keyword>I-ACQUIRE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public use dataset from the study data will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Approximately 1 year after primary data analysis publications</ipd_time_frame>
    <ipd_access_criteria>standard NIH criteria</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

